论文部分内容阅读
目的评价地特胰岛素联合二甲双胍治疗对肥胖型2型糖尿病患者的血糖、血脂和体重的影响。方法随机选择30例血糖控制不佳的肥胖型2型糖尿病患者,处方地特胰岛素联合二甲双双胍治疗3个月,观察治疗前(后的空腹血糖(FPG)、餐后2 h血糖(2 hPG)、HbAlc、三酰甘油(TG)、总胆固醇(TC)和体重指数(BMI)。结果地特胰岛素联合二甲双胍治疗3个月后,肥胖型2型糖尿病受试者的FBG、2hPG、HbA1 c、TG、TC均自基线显著降低(P<0.01);同时,受试者的肥胖程度得到显著改善,BMI从基线时的(27.5±2.5)kg/m2降至(26.5±1.5)kg/m2(P<0.01);试验过程中未观察到不良事件。结论地特胰岛素联合二甲双胍治疗,明显改善肥胖型2型糖尿病患者的高糖状态、脂代谢紊乱和肥胖程度。
Objective To evaluate the effect of insulin detemir plus metformin on blood glucose, blood lipid and body weight in obese type 2 diabetic patients. Methods 30 patients with type 2 diabetes mellitus with poor glycemic control were randomly selected and treated with insulin detemir and metformin for 3 months. The levels of fasting blood glucose (FPG), postprandial blood glucose (2) HbAlc, triglyceride (TG), total cholesterol (TC) and body mass index (BMI) were measured.Results After three months treatment with insulin and metformin, FBG, 2hPG and HbA1 in obese type 2 diabetic subjects (P <0.01). At the same time, the obesity level of the subjects was significantly improved, and the BMI decreased from (27.5 ± 2.5) kg / m2 at baseline to (26.5 ± 1.5) kg / m2 (P <0.01), no adverse events were observed during the course of the trial.Conclusion Detemir plus metformin significantly improves the hyperglycemia, lipid metabolism and obesity in obese type 2 diabetic patients.